PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 11736444

Search for new physics using QUAERO: a general interface to D0 event data.

V M Abazov·B Abbott·A Abdesselam·M Abolins·V Abramov·B S Acharya·D L Adams·M Adams·S N Ahmed·G D Alexeev·G A Alves·N Amos·E W Anderson·Y Arnoud·M M Baarmand·V V Babintsev·L Babukhadia·T C Bacon·A Baden·B Baldin·P W Balm·S Banerjee·E Barberis·P Baringer·J Barreto·J F Bartlett·U Bassler·D Bauer·A Bean·M Begel·A Belyaev·S B Beri·G Bernardi·I Bertram·A Besson·R Beuselinck·V A Bezzubov·P C Bhat·V Bhatnagar·M Bhattacharjee·G Blazey·S Blessing·A Boehnlein·N I Bojko·F Borcherding·K Bos·A Brandt·R Breedon·G Briskin·R Brock·G Brooijmans·A Bross·D Buchholz·M Buehler·V Buescher·V S Burtovoi·J M Butler·F Canelli·W Carvalho·D Casey·Z Casilum·H Castilla-Valdez·D Chakraborty·K M Chan·S V Chekulaev·D K Cho·S Choi·S Chopra·J H Christenson·M Chung·D Claes·A R Clark·J Cochran·L Coney·B Connolly·W E Cooper·D Coppage·S Crépé-Renaudin·M A Cummings·D Cutts·G A Davis·K Davis·K De·S J de Jong·K Del Signore·M Demarteau·R Demina·P Demine·D Denisov·S P Denisov·S Desai·H T Diehl·M Diesburg·G Di Loreto·S Doulas·P Draper·Y Ducros·L V Dudko·S Duensing·L Duflot
View original source ↗Export metadata ↓

Abstract

We describe QUAERO, a method that (i) enables the automatic optimization of searches for physics beyond the standard model, and (ii) provides a mechanism for making high energy collider data generally available. We apply QUAERO to searches for standard model WW, ZZ, and t t macro production, to searches for these objects produced through a new heavy resonance, and to the first direct search for W'-->WZ. Through this interface, we make three data sets collected by the D0 experiment at square root of [s] = 1.8 TeV publicly available.

Explore related subjects

Journal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

V M Abazov, B Abbott, A Abdesselam, M Abolins, V Abramov, B S Acharya, D L Adams, M Adams, S N Ahmed, G D Alexeev, G A Alves, N Amos, E W Anderson, Y Arnoud, M M Baarmand, V V Babintsev, L Babukhadia, T C Bacon, A Baden, B Baldin, P W Balm, S Banerjee, E Barberis, P Baringer, J Barreto, J F Bartlett, U Bassler, D Bauer, A Bean, M Begel, A Belyaev, S B Beri, G Bernardi, I Bertram, A Besson, R Beuselinck, V A Bezzubov, P C Bhat, V Bhatnagar, M Bhattacharjee, G Blazey, S Blessing, A Boehnlein, N I Bojko, F Borcherding, K Bos, A Brandt, R Breedon, G Briskin, R Brock, G Brooijmans, A Bross, D Buchholz, M Buehler, V Buescher, V S Burtovoi, J M Butler, F Canelli, W Carvalho, D Casey, Z Casilum, H Castilla-Valdez, D Chakraborty, K M Chan, S V Chekulaev, D K Cho, S Choi, S Chopra, J H Christenson, M Chung, D Claes, A R Clark, J Cochran, L Coney, B Connolly, W E Cooper, D Coppage, S Crépé-Renaudin, M A Cummings, D Cutts, G A Davis, K Davis, K De, S J de Jong, K Del Signore, M Demarteau, R Demina, P Demine, D Denisov, S P Denisov, S Desai, H T Diehl, M Diesburg, G Di Loreto, S Doulas, P Draper, Y Ducros, L V Dudko, S Duensing, L Duflot. 2001-11-14. Search for new physics using QUAERO: a general interface to D0 event data.. https://doi.org/10.1103/physrevlett.87.231801

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2027

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗